News & Updates
Filter by Specialty:

Low-dose aspirin prevents common GI cancers in Chinese adults without ASCVD
Low-dose aspirin reduces risks of some common gastrointestinal (GI) cancers, including colorectal cancer (CRC) and gastric cancer (GC), in Chinese without atherosclerotic cardiovascular disease (ASCVD), compared with paracetamol, the first population-wide study from the University of Hong Kong (HKU) has shown.
Low-dose aspirin prevents common GI cancers in Chinese adults without ASCVD
31 Mar 2022
Atezolizumab-bevacizumab combo trumps sorafenib for advanced HCC
The combination of atezolizumab and bevacizumab is better than sorafenib at maintaining clinically meaningful survival benefits over the long term in patients with unresectable hepatocellular carcinoma (HCC), reports a recent update to the IMbrave150 study.
Atezolizumab-bevacizumab combo trumps sorafenib for advanced HCC
27 Mar 2022
Polymeric immunoglobulin receptor boosts cancer stemness, tumorigenesis in HCC patients
Extracellular vesicles enriched with the polymeric immunoglobulin receptor molecule contributes to tumorigenesis and cancer stemness in patients with hepatocellular carcinoma (HCC), reports a recent study.
Polymeric immunoglobulin receptor boosts cancer stemness, tumorigenesis in HCC patients
26 Mar 2022
Moderate intake of dietary isoflavone lowers lung cancer risk in nonsmoking women
A moderate increase in the consumption of foods rich in isoflavone can help reduce the risk of lung cancer in women with no smoking history, suggests a study.
Moderate intake of dietary isoflavone lowers lung cancer risk in nonsmoking women
26 Mar 2022
Apalutamide for castration-resistant prostate cancer yields real-world results
Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who have been initiated on apalutamide in a real-world setting appear to show prostate-specific antigen (PSA) response that is strong and consistent with that reported in clinical trials, as reported in a study.
Apalutamide for castration-resistant prostate cancer yields real-world results
25 Mar 2022
Survival for breast cancer better now than 14 years ago
Breast cancer survival has been improving greatly over the last 14 years, an effect attributable to advancements in systemic therapy, a recent Korea study has found.